Biomarkers: Impact on Treatment Choices and Future Expectations
The key opinion leaders share their strategies for selecting systemic therapy, comparing immunotherapy combination (IO/IO) versus immunotherapy plus tyrosine kinase inhibitor (IO/TKI) approaches, for previously untreated patients with advanced renal cell carcinoma.
EP: 1.Current treatment options for ccRCC based on patient and disease factors
EP: 2.CheckMate-214: Long-term follow-up data
EP: 3.Review of CheckMate-214: Long-term follow-up in favorable risk subgroup
EP: 4.Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data
EP: 5.Review of KEYNOTE-426: Five-year Follow-up Data
EP: 6.Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens
EP: 7.Treatment-free survival in IO/TKI
EP: 8.Biomarkers: Impact on Treatment Choices and Future Expectations
EP: 9.Management of Adverse Events – IO/IO and IO/TKI
EP: 10.New formulations for current therapies – SC vs. IV
EP: 11.Novel Agents/Combinations for aRCC
- Dr McKay and Campbell: Please discuss your treatment approach to systemic therapy (IO/IO vs. IO/TKI) for treatment-naïve patients with advanced RCC.
- How do the most recent data updates for CM-214, CLEAR, KN-426, and CM-9ER impact your treatment decisions?
- Please discuss the importance of biomarkers in determining appropriate treatment options.
- CLEAR – biomarker analysis (Choueiri, TK, et al. 2024 ASCO Annual Meeting. Abstract 4504).
- CheckMate -214 – biomarker analysis (Matar, S, et al 2024 ASCO Annual Meeting. Abstract 4536).
- Keynote-426 – biomarker analysis (Rini BI, et al. 2024 ASCO Annual Meeting. Abstract 4505).
- Do you have a “go-to” treatment?
- How do you factor OS, PFS, and DOR into your decision-making?
- Does it differ for those with intermediate/poor risk vs. favorable risk disease?
- If so, what patient-specific variables would cause you to re-evaluate your treatment choice(s)?
- Age? Tumor burden? Kidney function? Performance status? Chronic comorbidities?
McGregor and Participants Discuss Impact of Drug Efficacy and Histology on nccRCC Care
October 17th 2024During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
